Wolverine Peptide Dosage: What Research Protocols Report
Wolverine peptide is not a single molecule and it is not an official drug name. In research notes it is the nickname for running two separate compounds together: BPC-157 and TB-500. This page collects the amounts those protocols report, how the timing usually differs between the two, and how to turn a vial label into a measurable volume. The figures are research-reported. They are not dosing advice, and neither peptide is approved for human consumption.
What the nickname actually refers to
BPC-157 is a synthetic 15 amino acid peptide related to a protective protein fragment found in gastric juice. Animal papers, many from the Sikiric group, test it in rodent models of tendon, gut lining, and blood vessel injury. A commonly cited exposure in those papers is about 10 micrograms per kilogram, and some report effects at nanogram per kilogram doses, so the animal literature is not one number. Method notes live on the BPC-157 protocol page.
TB-500, as sold for laboratory work, is usually a short synthetic fragment modeled on the actin-binding region of thymosin beta-4 (often the acetylated 17 to 23 sequence). Full-length thymosin beta-4 is 43 amino acids, and many cell-migration papers use that longer protein, not the fragment in a research vial. The single-peptide ranges are on the TB-500 dosage chart, with setup notes on the TB-500 protocol page.
Why protocols pair them
The pairing is a community research pattern, not a finished clinical program. BPC-157 papers emphasize local repair signaling in animal tissue. Thymosin beta-4 papers emphasize actin handling and cell migration. No large controlled human trial has tested the combination as a product, so the chart below extrapolates from those separate literatures plus ranges repeated in laboratory protocols.
Research-reported dosage chart
The ranges below match the single-peptide charts already published on this site. They describe what appears in research protocols. They are not instructions to administer anything.
| Peptide | Phase | Research-reported amount | Frequency in protocols |
|---|---|---|---|
| BPC-157 | Full block | 250 to 500 mcg per day | Once daily, or split twice daily |
| TB-500 | Loading, first 4 to 6 weeks | 4 to 10 mg per week | Split into 2 doses in the week |
| TB-500 | Maintenance after loading | 2 to 6 mg per week | Once weekly, or every 2 weeks |
A common pattern keeps BPC-157 on a daily schedule for the whole block while TB-500 is front-loaded, then reduced. Broader BPC-157 writeups sometimes cite 250 to 350 mcg, or up to about 750 mcg in aggressive logs. The 250 to 500 mcg band is the overlap most often cited for the pair. Detail on BPC-157 alone is in the BPC-157 dosage chart.
How long the block usually runs
Protocols that use the nickname usually describe 4 to 6 weeks, lined up with the TB-500 loading window. Some notes then stop TB-500, or drop it to maintenance, and either stop BPC-157 or carry the daily exposure a few more weeks. A break after the block is common. There is no clinical rule for that pause. It only keeps the observation tied to a defined window.
Animal microgram per kilogram data does not convert cleanly into these fixed amounts. A 10 microgram per kilogram rodent dose is not the same statement as 250 mcg on a bench card. Route, peptide form (fragment versus full length), and the injury model all change what the number means.
Reconstitution math for two different scales
Each vial needs its own concentration. Record the water volume and divide before any aliquot is pulled. The peptide dosage calculator does that from vial size and water volume.
- BPC-157 example: a 5 mg vial reconstituted with 2 ml yields 2.5 mg/ml, which is 2500 mcg/ml. A 250 mcg research amount is 0.1 ml (10 units on a U-100 insulin syringe). A 500 mcg amount is 0.2 ml.
- TB-500 example: a 5 mg vial reconstituted with 2.5 ml yields 2 mg/ml. A 2 mg research amount is 1 ml. A 2.5 mg amount is 1.25 ml. Weekly totals in the chart are the sum of those pulls, not a single daily figure.
If a supplier sells a combined lyophilized vial, ignore the nickname and use only the printed milligrams of each peptide. Most careful logs keep the vials separate so a bad response can be traced to one compound.
What is not established
Human safety and efficacy for the combination are not established. Each peptide already has a thin clinical record on its own, and the pair has less. Notes on the separate compounds include injection-site redness, a short-lived lump, headache, and transient fatigue. Whether those show up more often together is unknown. Long-term data, drug interactions, and pregnancy are unknown. An under-filled or contaminated vial will not match any row in the table, so identity and purity testing sit upstream of any dosage discussion.